Stryker Co. (NYSE:SYK) is Dillon & Associates Inc.’s 5th Largest Position

Dillon & Associates Inc. lowered its position in shares of Stryker Co. (NYSE:SYK) by 0.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 85,829 shares of the medical technology company’s stock after selling 464 shares during the period. Stryker comprises about 4.3% of Dillon & Associates Inc.’s holdings, making the stock its 5th largest holding. Dillon & Associates Inc.’s holdings in Stryker were worth $30,898,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker in the 4th quarter worth approximately $25,000. Dunhill Financial LLC lifted its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. raised its holdings in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC bought a new position in Stryker in the 4th quarter worth $30,000. Finally, BankPlus Trust Department bought a new position in Stryker in the 4th quarter worth $33,000. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Citigroup restated a “buy” rating and set a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. JPMorgan Chase & Co. increased their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Royal Bank of Canada upped their price target on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Argus set a $450.00 target price on shares of Stryker in a report on Monday, February 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Friday. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Stock Performance

Shares of SYK opened at $371.38 on Monday. The business’s 50 day moving average is $384.28 and its two-hundred day moving average is $374.12. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The firm has a market cap of $141.71 billion, a price-to-earnings ratio of 47.86, a PEG ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 earnings per share. Analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.